Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar 30;215(4):518–528. doi: 10.1093/infdis/jiw608

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

PMC Copyright notice

Figure 2. — Intrasubtypic antibody responses against heterologous H7 viruses in H7N9 infected patients. A, Neutralizing antibody (nAb) titers (log2) against EN96 H7 (left), NL03 H7 (middle), or WA07 H7 (right) pseudoviruses. B, Hemagglutination inhibition (HAI) titers (log2) against EN96 H7 (left), NL03 H7 (middle), or WA07 H7 (right) pseudoviruses. Serum samples from 18 H7N9-infected patients were collected at the early (gray) or late (dark) stages of infection as indicated above, and nAb or HAI titers were quantified using pseudovirus-based neutralization or HAI assays. Sera from 8 uninfected patients (red) were used as controls. The rate of seroconversion (SC) of HAI or nAb against pseudotyped viruses was defined as titers ≥40 or 4-fold increases. C, Dynamic nAb titers (log2) against EN96 H7 (●), NL03 H7 (■), or WA07 H7 (▲) were quantified in patients 1, 3, 4, 7, 8, and 9 using a pseudovirus-based assay. Dynamic nAb titers (log2) against homologous H7 virus SH13 H7 (red ○) were used as reference. The gray dashed line represents the geometric mean of the uninfected controls.